Ritonavir
An antiretroviral drug originally used to treat HIV, now most commonly used at low doses as a pharmacokinetic booster to increase the blood levels of other protease inhibitors and antiviral drugs. By inhibiting the CYP3A4 enzyme, it slows the breakdown of companion drugs and allows them to be taken less frequently.
Peso Molecular
720,9000 g/mol
LogP
6,00
TPSA
202,00 Ų
Regra dos 5 de Lipinski
Reprovado
Áreas Terapêuticas
Mecanismo de Ação
Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
InChI
InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1
Molecular Formula
C37H48N6O5S2
HBD / HBA
4 / 9
Ligações Rotacionáveis
18
Átomos Pesados
50
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
An antiretroviral drug originally used to treat HIV, now most commonly used at low doses as a pharmacokinetic booster to increase the blood levels of other protease inhibitors and antiviral drugs. By inhibiting the CYP3A4 enzyme, it slows the breakdown of companion drugs and allows them to be taken less frequently.
Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.
Yes, Ritonavir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL163. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 392622. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ritonavir"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ritonavir/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ritonavir/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ritonavir/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ritonavir"></drugfyi-drug>